EOM Pharmaceutical Holdings, Inc.
IMUC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMUC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2018.
Tracking 1 pipeline candidate for EOM Pharmaceutical Holdings, Inc..
Similar companies
Run EOM Pharmaceutical Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available EOM Pharmaceutical Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
4.3 months
D/E 0.12
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 4.0%
- Days to cover
- 4.1
- Shares short
- 165,946
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMUC short interestFrequently asked questions
What is EOM Pharmaceutical Holdings, Inc.'s lead drug candidate?
EOM Pharmaceutical Holdings, Inc.'s most advanced tracked candidate is ict-107 (Phase 3) for newly diagnosed glioblastoma.
Who is the CEO of EOM Pharmaceutical Holdings, Inc.?
Dr. Irach B. Taraporewala B.S., M.S., Ph.D. is the chief executive officer of EOM Pharmaceutical Holdings, Inc. (IMUC).
Where is EOM Pharmaceutical Holdings, Inc. headquartered?
EOM Pharmaceutical Holdings, Inc. (IMUC) is headquartered in Montvale, NJ, United States.
What therapeutic areas does EOM Pharmaceutical Holdings, Inc. focus on?
EOM Pharmaceutical Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.